Pubications

Clinical Drug Development Consulting AG (Ltd)

1. POKORNY R. "Programme zu einem on-line Verfahren zur klassifizierten Mittelung evozierter Potentiale nach dem Leistungsspektrum des EEG durch ein Laborrechner- Mikroprozessor-System" Interdisziplinäres Modell DORA, Arbeitsbericht D4-10, 1983

2. POKORNY R. "Ein on-line Verfahren zur klassifizierten Mittelung evozierter Potenti­ale nach dem Leistungsspektrum des EEG durch ein Laborrechner Mikroprozessor-System" Inaugural-Dissertation Universität Erlangen-Nürnberg, 1983

3. Yamadera H, Matejcek M, Ferber G, POKORNY R. "Electroencephalographic and Psychometric Assessment of the CNS Effects of Single Doses of Guanfacine hydrocloride (Estulic) and Clonidine (Catapres)" Neuropsychobiology 1985; 14: 97 - 107

4. Yamadera H, Matejcek M, Ferber G, POKORNY R. "Pharmaco EEG and Psychomet­ric Study of the CNS Effects of Single Doses of Guanfacine hydrochloride (Estulic) and Clonidine (Catapres)" Electroenceph. and Clinical Neurophysiology 1985; 61 (3): 113 ff

5. POKORNY R, Ferber G, Matejcek M, Klee H. "Die Beeinflussung von Augenfolge­bewegungen durch Pharmaka" Z. EEG-EMG 1986; 17: 41

6. POKORNY R, Ferber G, Matejcek M, Klee H. "Vergleich der Wirkung von Phar­maka auf das EEG und die Augenfolgebewegungen" Z. EEG-EMG 1986; 17: 169

7. POKORNY R, Ferber G, Matejcek M, Irwin P, Klee H. "The Influence of Drugs on Eye Tracking Tasks" Neurophysiology 1986; 65: 12

8. POKORNY R, Ferber G, Matejcek M, Irwin P, Klee H. "Die Beeinflussung von Augenfolgebewegungen durch Pharmaka" Schweiz. Arch. Neurol. Psychiat. 1986; 137: 78

9. POKORNY R, Matejcek M, Klee H, Ferber G. "Comparison of the CNS-effects of different galenical forms of the same Compound by Means of Electroencephalography" IPEG Symposium 1986, Sta. Margherita, Italy

10. POKORNY R, Matejcek M, Ferber G, Klee H. "The Effect of Morphine on the EEG and on other psychological and Behavioral Parameters" IPEG Symposium 1986, Sta. Mar­gherita, Italy

11. POKORNY R, Klee H, Matejcek M, Ferber G. "Requirements for the Investigation of Acute Drug Effects on Eye Movements in Healthy Subjects" 4th European Conference on Eye Movements, Göttingen, 1986; Vol. 1: Proceedings, Ed.: Lüer G., Lass U., Hogrefe C.J.

12. Ferber G, POKORNY R, Klee H, Matejcek M. "CNV as a Tool to assess Drug Effects on the Brain" 11. Int. Conference on Dynamics of Sensory and Cognitive Processing by the Brain 1987, Berlin

13. Yamadera H, Ferber G, Matejcek M, POKORNY R. "Quantitative Pharmaco- electroencephalographic Differentiation between the CNS Effects of Bromocriptine and Imipramine, Drugs with qualitatively different antidepressant properties" Pharmacopsy­chiatry 1987; 20: 54 - 59

14. Matejcek M, POKORNY R, Ferber G, Klee H. "The Effects of Morphine on the EEG and other physiological and behavioral parameters" Neuropsychobiology 1988; 19 (4): 202 - 211

15. POKORNY R, Klee H, Matejcek M, Ferber G, Danis P. "Die P300 unter unterschied­lichen Versuchsbedingungen und das Ressourcenmodell" Z. EEG-EMG 1988; 19:

16. Ferber G, Klee H, Matejcek M, POKORNY R. "Combined Analysis of the Effects of Single Doses of Haloperidol Assessed by Means of EEG, CNV and Symptom Ratings" IPEG Symposium 1988, Kobe/Japan

17. Matejcek M, POKORNY R, Ferber G, Klee H. "The Effects of Morphine on the EEG and other Physiological and Behavioral Parameters" IPEG Symposium 1988, Kobe/Japan

18. POKORNY R, Klee H, Matejcek M, Ferber G. "Zwei Verfahren zur automatischen Vermessung der P300-Welle" Z. EEG-EMG 1989; 20:

19. Maurer K, POKORNY R. "Clinical Relevance and Interpretation of Topographic EEG and Evoked Potential(EP) Mapping" Pharmacopsychiat. 1990; 23: 235

20. Denzlinger C, Gerhartz HH, Tetzloff W, POKORNY R, Wilmanns W. "Role of En­dogenous Leukotriene Production in the Actions of Ganulocyte-Macrophage Colony- Stimulating Factor in Man" Eicosanoids and other Bioactive Lipids in Cancer, Inflamma­tion and Radiation Injury, 2nd International Conference, 1991, Berlin

21. de Vries E, POKORNY R, Kovarik JM, Duffy F. "Study of Tolerability, Safety and Pharmacokinetics of iv and sc Human Recombinant IL-3 (RhIL-3, SDZ ILE 964) to Pre­vent Bone Marrow Depression During Chemotherapy for Ovarian Carcinoma" Eighty- Third Annual Meeting of the American Association for Cancer Research, 1992, San Diego, California

22. Rockstroh S, POKORNY R, Kirkesseli S, Kutz K.. Effekte eines atypischen Neuroleptikums auf Aufmerksamkeitsprozesse. Zeitschrift für Neuropsychologie, , 1992, 3, 120-129

23. POKORNY R, Tetzloff W. Koelle EU, Abisch E. "Pharmacokinetics and Pharmaco­dynamics of two Different Preparations of Granulocyte-Macrophage Colony-Stimulating Factor" Naunyn-Schmiedebergs Archives of Pharmacology Herbsttagung der deutschen Gesellschaft für Pharmakologie und Toxikologie, 1992, Graz, Austria

24. Denzlinger C, Tetzloff W, Gerhartz HH, POKORNY R, Sagebiel S, Haberl C, Wil­manns W. "Differential activation of endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers" BLOOD 1993; Vol 81 (8):, 2007-2013

25. Biesma B, POKORNY R, Kovarik JM, Duffy F, Willemse PHB, Mulder NH, de Vries EGH. "Pharmacokinetics of recombinant human Interleukin-3 administered subcu­taneously and by continuous intravenous infusion in patients after chemotherapy for ovar­ian cancer" Cancer Res 1993; 53: 5915-5919

26. Francheteau P, Tarral A, Merdjan H, Hubert M, Abousahl I, Court LA, POKORNY R. "A Population Pharmacokinetics-Pharmacodynamic (PK-PD) Analysis of in Vivo Central Nervous System (CNS) Drug Effects Assessed by Quantitative Electroen­cephalography (EEG) in Human Volunteers" Symposium Measurement and Kinetics of in Vivo Drug Effects, 1994, Noordwijkerhout, The Netherlands

27. Emre M, Leslie GC, Muir C, Part NJ, POKORNY R, Roberts RC. "Correlations between dose, plasma concentrations, and antispastic action of tizanidine (SirdaludR)" J Neurol Neurosurg Psychiatry 1994; 57: 1355 – 1359

28. Roberts RC, Part NJ, POKORNY R, Muir C, Leslie GC, Emre M. " Pharmacokinetics and pharmacodynamics of tizanidine" Neurology 1994, Vol: 44(11 Suppl 9): 29 – 31

29. Roberts RC, Part NJ, POKORNY R, Muir C, Leslie GC, Emre M. " Pharmacokinetics and pharmacodynamics of tizanidine" Neurology 1994, Vol: 44(11 Suppl 9): 29 - 31

30. POKORNY R, Finkel MJ, Robinson WT "Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine (letter)" Pharm Res 1994, Vol: 11 (8), p 1221

31. Tarral A, Rockstroh S, POKORNY R, Dubray C. " Effects of SDZ EAA 494, a Novel NMDA-Receptor Antagonist, on Memory and Attention" ASSOCIATION FRANCAISE DES PHARMACOLOGISTES -52EME REUNION-13 & 14 October 1994. Fundam-Clin-Pharmacol 1995; No 1, 9: 86

32. Rockstroh S, Dietrich B, POKORNY R.” Memory and attention test performance of young and elderly subjects after retest practice” Int-Psychogeriatr 1995 Fall, Vol: 7(3): 377 – 384

33. Rockstroh S, Emre M, Tarral A, POKORNY R. "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans" Psychopharmacology 1996; 124: 261 – 266

34. Rockstroh S, POKORNY R, Tarral A. Aufmerksamkeitseffekte des neuen Alpha1-Agonisten Naphthoxazin mit möglicher Indikation beim ADDH. Zeitschrift für Neuropsychologie, 1999, 10, 250-251

35. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, POKORNY R, Seiberling M. ‘’Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects’’
Cancer Chemother Pharmacol (2004) 54: 290–294

36. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, POKORNY R, Capdeville R, Lloyd P. ‘’ Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion’’
J Clin Pharmacol. 2004 Feb;44(2):158-62

37. Von Krempelhuber A, Vollmar J, POKORNY R, Seiberling M, Nauer T, Rapp P, Petzold B, Handley A, Wulff NH, Chaplin P. ‘Third Generation Smallpox Vaccine IMVAMUNE™ A Double-blind, Randomised Phase II Dose Finding Trial with 165 Vaccinia Naïve Subjects’’
Poster ‘’Interscience Conference on Antimicrobial Agents and Chemotherapy“ (ICAAC), Washington, October 2004

38. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, POKORNY R, Seiberling M, Ben-Am M, Peng B, Gross G. ‘Metabolism and disposition of imatinib mesylate in healthy volunteers’
Drug Metabolism and Disposition 2005, 33(10): 1503–1512

39. Schmid-Grendelmeier P, POKORNY R, Gasser UE, Richarz U. ‘A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers’
Curr Med Res Opin 2006 Mar;22(3): 501 - 509

40. Koltzenburg M, POKORNY R, Gasser UE, Richarz U. ‘Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine’ Pain 2006 Aug 8;

41. Anand R, Seiberling M, Kamtchoua T, POKORNY R. ‘Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers
Clinical Pharmacokinetics 2007, 46(4): 351-358

42. Lubenau H, POKORNY R, Lopez-Lazaro L, Bias P, Bruce W, Hinderer W, Maly AK, Seiberling M. ‘GlycoPEGylated filgrastim XM22 demonstrates dose-dependent activity in comparison to Pegfilgrastim in a dose-escalating study in healthy volunteers after body-weight dependent single dose’, Blood 2007, 110(11) : 89B

43. Lubenau H, POKORNY R, Lopez-Lazaro L, Bias P, Bruce W, Hinderer W, Maly AK, Seiberling M. ‘GlycoPEGylated filgrastim XM22 fixed dose demonstrates similar activity in comparison to Pegfilgrastim in healthy volunteers after single administration’, Blood 2007, 110(11) : 89B

44. Lubenau H, POKORNY R, Lopez-Lazaro L, Bias P, Wallin B, Hinderer W, Seiberling M. GlycoPEGylated G-CSF XM22 Demonstrates Sixty Percent Higher Bioavailability and Thirty Percent Greater Neutrophil Response in Comparison to Pegfilgrastim in Healthy Volunteers after Single Body Weight Dependent and Fixed Dose, Can J Clin Pharmacol Vol 15 (3) Fall 2008:e420-e781; November 5, 2008

45. Lazar H, Horn MP, Zuercher AW, Imboden MA, Durrer P, Seiberling M, POKORNY R, Hammer C, Lang AB. ‘Pharmacokinetics and safety profile of the human anti P. aeruginosa sero-type O11 IgM monoclonal antibody KBPA-101 in healthy volunteers’
Antimicrobial Agents and Chemotherapy, Aug 2009, 3442-3446
doi:10.1128/AAC.01699-08

46. Von Krempelhuber A, Vollmar, J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateoa L, Siersbol H, Kollaritsch H, Chaplin P.
’A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®’
Vaccine Volume 28, Issue 5, 3, 2010: 1209-1216

47. Patel H, Andersen H, Vente A, Heilmann HD, Seiberling M, Lopez-Lazaro L, POKORNY R, Labischinski H. ‘Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers’, Antimicrob. Agents Chemother. September 2011 vol. 55 no. 9 4386-4393

48. Morris CA, Lopez-Lazaro L, Jung D, Methaneethorn J, Duparc S, Borghini-Fuhrer I, POKORNY R, Chang-Sik Shin and Fleckenstein L.´Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers’, Am J Trop Med Hyg 2012 vol. 86 no. 3 489-495

49. Varadi G, Zhu Z, Blättler T, Hösle M, Loher A, POKORNY R, Frey D, and Carter SG. 'Randomized Clinical Trial Evaluating Transdermal Ibuprofen for Moderate to Severe Knee Osteoarthritis', Pain Physician 2013; 16:E749-E762

50. Black R, Lues I, Weber F, Meyer A, Hoffman T, POKORNY R, Demuth HU, Glund K. 'Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly', Alzheimer’s & Dementia: July 2013 Volume 9, Issue 4, Supplement, Page P280. DOI: http://dx.doi.org/10.1016/j.jalz.2013.05.559

51. Morris CA, POKORNY R, Lopez-Lazaro L, Miller RM, Arbe-Barnes S, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L. 'Pharmacokinetic interaction between pyronaridine/artesunate and metoprolol', Antimicrob. Agents Chemother. 2014; vol. 58 no. 8

52. Mathis GA, Toggenburger A, POKORNY R, Autzen S, Ibanez R, Romeis P, Bachmann P. 'Human pharmacokinetic profile of 1,25-dihydroxyvitamin D3-glycoside of herbal origin', Journal of Steroid Biochemistry & Molecular Biology 2014 vol. 144; 40–43

53. Morris CA, Dueker SR, Lohstroh PN, Wang LQ, Fang XP, Jung D, Lopez-Lazaro L, Baker M, Duparc S, Borghini-Fuhrer I, POKORNY R, Shin JS, Fleckenstein L. 'Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers', Eur J Drug Metab Pharmacokinet March 2014
DOI10.1007/s13318-014-0182-0

54. Lues I, Weber F, Meyer A, Bühring U, Hoffmann T, Kühn-Wache K, Manhart S, Heiser U, POKORNY R, Chiesa J, Glund K. 'A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects', Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 182-195

Share by: